| Reference | </br>1: Li A, Song Z. Study of silver nanoparticles sensitized fluorescence and</br> second-order scattering of terbium(III)-pefloxacin mesylate complex and</br> determination of pefloxacin mesylate. ScientificWorldJournal. 2014;2014:742935.</br> doi: 10.1155/2014/742935. Epub 2014 May 6. PubMed PMID: 24892083; PubMed Central </br> PMCID: PMC4032712.</br>2: Guo M, Lu XW, Ran XY, Hu RH. [Molecular transport mechanism of pefloxacin</br> mesylate binding with transferrin]. Yao Xue Xue Bao. 2012 Nov;47(11):1503-10.</br> Chinese. PubMed PMID: 23387084.</br>3: Liu Y, Huang Y, Liu J, Wang W, Liu G, Zhao R. Superparamagnetic surface</br> molecularly imprinted nanoparticles for water-soluble pefloxacin mesylate</br> prepared via surface initiated atom transfer radical polymerization and its</br> application in egg sample analysis. J Chromatogr A. 2012 Jul 13;1246:15-21. doi: </br> 10.1016/j.chroma.2012.01.045. Epub 2012 Jan 25. PubMed PMID: 22321951.</br>4: Liu R, Li N, Liu N, Zhou X, Dong ZM, Wen XJ, Liu LC. Effects of systemic</br> ornidazole, systemic and local compound ornidazole and pefloxacin mesylate on</br> experimental periodontitis in rats. Med Sci Monit. 2012 Mar;18(3):BR95-102.</br> PubMed PMID: 22367122; PubMed Central PMCID: PMC3560749.</br>5: Xie Y, Song Y, Zhang Y, Zhao B. Near-infrared spectroscopy quantitative</br> determination of pefloxacin mesylate concentration in pharmaceuticals by using</br> partial least squares and principal component regression multivariate</br> calibration. Spectrochim Acta A Mol Biomol Spectrosc. 2010 May;75(5):1535-9. doi:</br> 10.1016/j.saa.2010.02.012. Epub 2010 Feb 21. PubMed PMID: 20299275.</br>6: Deng B, Li L, Shi A, Kang Y. Pharmacokinetics of pefloxacin mesylate in human </br> urine using capillary electrophoresis electrochemiluminescence detection. J</br> Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2585-8. doi:</br> 10.1016/j.jchromb.2009.06.021. Epub 2009 Jun 21. PubMed PMID: 19576860.</br>7: Basavaiah K, Prameela HC, Somashekar BC. Spectrophotometric determination of</br> pefloxacin mesylate in pharmaceuticals. Acta Pharm. 2007 Jun;57(2):221-30. PubMed</br> PMID: 17507318.</br>8: Fan JC, Chen X, Wang Y, Fan CP, Shang ZC. Binding interactions of pefloxacin</br> mesylate with bovine lactoferrin and human serum albumin. J Zhejiang Univ Sci B. </br> 2006 Jun;7(6):452-8. PubMed PMID: 16691639; PubMed Central PMCID: PMC1473993.</br>9: Sultana Y, Aqil M, Ali A. Ion-activated, Gelrite-based in situ ophthalmic gels</br> of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 2006 </br> May-Jun;13(3):215-9. PubMed PMID: 16556574.</br>10: Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of</br> pefloxacin mesylate: preparation and evaluation. Acta Pharm. 2005</br> Sep;55(3):305-14. PubMed PMID: 16375841.</br>11: Bharath S, Hiremath SR. Ocular delivery systems of pefloxacin mesylate.</br> Pharmazie. 1999 Jan;54(1):55-8. PubMed PMID: 9987797.</br>12: Isaacs RD, Ellis-Pegler RB. Successful treatment of Morganella morganii</br> meningitis with pefloxacin mesylate. J Antimicrob Chemother. 1987</br> Nov;20(5):769-70. PubMed PMID: 3480886.</br>13: Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate, and</br> elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.</br> Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. PubMed PMID: 6587830; PubMed </br> Central PMCID: PMC185553.</br>14: Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of carbopol-methyl cellulose</br> based sustained-release ocular delivery system for pefloxacin mesylate using</br> rabbit eye model. Pharm Dev Technol. 2006;11(3):313-9. PubMed PMID: 16895842.</br>15: Chao JB, Tong HB, Liu DS, Huang SP. Preparation and characterization of</br> inclusion complexes of pefloxacin mesylate with three kinds of cyclodextrins.</br> Spectrochim Acta A Mol Biomol Spectrosc. 2006 May 1;64(1):166-70. Epub 2005 Aug</br> 10. PubMed PMID: 16098803.</br>16: Sultana Y, Jha MC, Ali A, Aqil M. A three-way comparative study on the</br> efficacy of twin sol to gel systems and marketed eye drops of pefloxacin</br> mesylate. J Ocul Pharmacol Ther. 2004 Aug;20(4):363-71. PubMed PMID: 15321031.</br>17: Pozdniakova VP, Nestetrova LIa, Smirnova LB, Iakovlev VP, Blatun LA, Koshil/’ </br> OI, Fedorov SM, Bakalova LA, Strachunskiĭ LS, Kurmanova KB. [Pefloxacin</br> mesylate–clinical effectiveness in various forms of infectious-inflammatory</br> diseases]. Antibiot Khimioter. 1997;42(7):20-3. Russian. PubMed PMID: 9334143.</br>18: Rose TF, Ellis-Pegler R, Collins J, Small M. Oral pefloxacin mesylate in the </br> treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an</br> open non-comparative study. J Antimicrob Chemother. 1990 May;25(5):853-9. PubMed </br> PMID: 2373667.</br></br>
|
